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Abstract 
 
Infantile hemangioma (IH) is the most common tumour of infancy.  The 
recommended treatment for IH is a non-selective β-adrenergic receptor antagonist, 
propranolol.  Although propranolol is effective in regressing hemangiomas, the 
mechanism of its action is poorly understood.  Moreover, some hemangiomas 
regrow following cessation of treatment.  We have recently shown that IH arise from 
multi-potent stem cells.  Whether IH stem cells are responsive to propranolol is 
unknown and is the focus of this study.  Hemangioma-derived stem cells and 
vascular endothelial cells were exposed to propranolol and were assayed for cellular 
and molecular alterations.  Our studies show that propranolol inhibits the growth of 
hemangioma stem cells but does not cause apoptosis.  We further show that the 
mechanism may involve serotonin receptors in hemangioma stem cells.  These 
findings are in contrast to endothelial cells, which exhibit apoptosis potentially 
through the action of propranolol on β-adrenergic receptors.  This study reveals that 
propranolol’s therapeutic effect is β-adrenergic receptor-independent in 
hemangioma-derived stem cells.   
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Chapter 1  
1 Introduction1,2  
1.1 Infantile hemangioma 
Infantile hemangioma (IH) is the most common vascular tumour of infancy, 
affecting one of every 100 newborns [1, 2].  For reasons unknown, IH affects 
more females than males, and is also more prevalent in premature and 
Caucasian babies [3, 4].  IH is often noticed soon after birth where approximately 
80% of these lesions are found in the head and neck regions, but they can be 
located elsewhere in the body [5-7].  It has been well-established that IH follows 
three developmental phases [8, 9].  The first phase entails expansion of 
undifferentiated tumour cells [10, 11].  This proliferating stage is completed by 8 
months of age in most cases [11].  In the following involuting phase, these 
tumour cells differentiate into atypical vascular endothelial cells (ECs) [12, 13].  
Uniquely, IH endothelium exhibits robust expression of glucose transporter-1 
(Glut1) [14, 15].  The involuting phase, like the proliferating phase, is a continuum 
of cellular and molecular changes with the end result being appearance of 
adipocytes and fibrofatty residuum [8, 9, 13].  Most IHs resolve spontaneously 
and do not require treatment [16].  However, therapeutic intervention is 
necessary in cases where the lesion grows in certain locations and to sizes that 
could result in life-threatening complications.  An example of such a situation is 
the growth of IH in the airway to obstruct the respiratory system [17]. 
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1 Parts of this chapter have been published: Kum JJY, Khan ZA.  Mechanisms of 
propranolol action in infantile hemangioma.  Dermato-Endocrinology.  2014; 6:1, 
e979699, DOI: 10.4161/19381980.2014.979699.  Dermato-Endocrinology 
applies the Creative Commons Attribution License (CC-BY Attribution 2.0) to 
works.  Under this license, authors retain ownership of the copyright for their 
content.  No permission is required from the publishers.   
2 Parts of this chapter have been published: Kum JJY, Khan ZA.  Propranolol 
inhibits growth of hemangioma-initiating cells but does not induce apoptosis.  
Pediatric Research.  2014;75:381-8.  DOI:10.1038/pr.2013.231.  Pediatric 
Research applies the Nature Publishing Group (NPG) author licence policy to 
works.  Under the license, authors retain ownership of the copyright for their 
published contributions.  No permission is required from the publisher of the 
journal. 
 
1.2 Treatment options for hemangioma 
Although many attempts have been made, the treatment guidelines for IH are not 
fully established due to differential effects of diverse therapeutic options, the 
differences in the location, stage, and size of the tumour, and the age of patients 
[16].  Typically, treatment is initiated as soon as possible to avoid unnecessary 
disfigurement as hemangioma growth is highly unpredictable.  Hence, many 
treatments are introduced during the early proliferative phase of IH.  Currently, 
laser treatments, β-blockers, surgery and corticosteroids are available for 
hemangioma patients [18-21].  Although many treatment options are available, 
the therapeutic mechanism of action of the pharmacological treatment options is 
poorly understood.  Many studies suggest that treatments target the anti-
angiogenic pathway to reduce the rapid growth of blood vessels during the early 
proliferative phase of hemangiomas.   
Corticosteroids were once considered to be a standard treatment for 
hemangiomas.  Unfortunately, high doses of systemic corticosteroid treatment 
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over extended periods of time have produced severe side effects including 
severe growth retardation, immunosuppression, and inhibition of wound healing 
[22, 23].   
Propranolol is a synthetic non-selective β-adrenergic receptor (β-ADR) 
antagonist, commonly referred to as a β-blocker.  It is a commonly used drug for 
cardiac complications, such as hypertension and myocardial infarctions.  In 2008, 
propranolol was accidentally found to be an effective pharmacological alternative 
for hemangiomas in two infants [24].  These infants, while receiving 
corticosteroids for hemangioma, were also given propranolol to treat cardiac 
complications.  Upon propranolol treatment, hemangiomas regressed rapidly in 
these patients.  Since then, propranolol has been used world-wide as the first-
line treatment option for hemangioma patients.  Many studies have compared 
corticosteroids and propranolol use for hemangiomas, and it has been shown 
that propranolol is more effective with minimal side effects when compared to 
corticosteroid use [24, 25].   
Despite remarkable efficacy of propranolol [26], there are some adverse effects, 
which include sleep disturbances, acrocyanosis, hypotension, and hypoglycemia 
[25, 27, 28].  There are also reports of IH regrowth following cessation of 
treatment in as many as 20% of the cases [29, 30].  Therefore, greater 
understanding of the potential mechanisms underlying the therapeutic effect is 
needed to develop better and safer treatment options.  Many mechanisms have 
been proposed, though only tested in culture studies, to explain the therapeutic 
mechanism of propranolol in treating IH.  Theories involving vasoconstriction 
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[31], EC apoptosis via β-ADR signaling [32, 33] and caspase activation [34, 35], 
and inhibition of angiogenesis via the modulation of vascular growth factors [33, 
36, 37] have been suggested.   
 
1.3 β-adrenergic receptors (β-ADRs) 
Propranolol has been known to bind to β-ADRs.  β-ADRs are a family of G 
protein-coupled receptors (GPCRs) that mediate physiological responses to 
adrenaline and noradrenaline.  It has been previously shown that the 
transmembrane region of β-ADRs play a critical role in determining the binding of 
selective agonists/antagonists [38].  To date, three subtypes of β-ADRs have 
been identified: β1-3 ADRs.  There is limited information available on β1-3 ADR 
distribution at the cellular and tissue levels.  Highest levels of β1-ADR are 
thought to be observed in the heart and brain [39].  β2-ADR shows a wide 
distribution pattern and β3-ADR is believed to be predominantly expressed in 
adipose tissue [40, 41].  In blood vessels, studies have utilized β-ADR antagonist 
binding to show sites in all cellular layers of vessels [42, 43].  Predominant ADR 
subtypes in vessels include β1- and β2- as confirmed by β-ADR subtype 
knockout studies [42].  Using immunohistochemistry, β1- and β2-ADR proteins 
have been localized to IH endothelium (co-localized to CD31-positive cells) as 
well as perivascular cells (co-localized to α-smooth muscle actin-positive cells) 
[44, 45].  In addition, β3-ADR has also been reported in all phases of IH [37].  
Given that β-ADRs are present in normal vessels and IH vessels, the question 
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arises as to the role of β-ADRs in vessel function and the effect of β-ADR 
blockade in IH resolution.   
1.3.1 β-ADR signaling events  
β-ADRs associate with downstream signaling molecules upon activation (Figure 
1).  β1 and β3 generally couple with Gs (stimulatory) proteins, whereas β2 may 
couple with Gs or Gi (inhibitory).  In the unstimulated state, the trimeric G protein 
is bound to GDP.  Activation of ADRs promotes exchange of GDP for GTP.  The 
G protein α subunit with bound GTP then dissociates from the β and γ subunits 
to activate adenylate cyclase (AC) and increase intracellular cyclic adenosine 
monophosphate (cAMP) levels.  Gi may counteract this increase by inhibiting AC.  
Intracellular cAMP activates cAMP-dependent protein kinase A (PKA) which may 
have multiple cellular consequences [46].  For example, PKA has been shown to 
be involved in elaboration of angiogenic factors through cAMP response 
element-binding protein (CREB) [47].  In addition to PKA-mediated signaling, 
activated AC may also activate mitogen-activated protein kinase (MAPK) 
pathway through exchange protein activated by adenylate cyclase (EPAC) [48, 
49].  Dissociated Gβγ may also lead to activation of phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3 kinase) and Akt/protein kinase B.  Interestingly, it has 
been shown that Akt activation can ultimately increase vessel size and 
angiogenesis [50].  In addition, ADR signaling may entail a G protein 
independent signaling pathway.  A well-characterized example is the β-arrestin-
mediated activation of MAPK pathways [51, 52].  Involvement of these pathways 
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indicates that inhibiting β-ADR through propranolol in IH may, indeed, have 
beneficial effects by reducing cell survival as well as inhibiting angiogenesis.   
 
Figure 1: Schematic illustrating β-ADR signaling.   
Ligand binding to β-ADRs results in Gs-mediated activation of adenylate cyclase 
(AC) and conversion of ATP into cAMP.  Intracellular cAMP activates PKA to 
phosphorylate target proteins.  cAMP may also activate exchange protein 
activated by adenylate cyclase (EPAC) leading to mitogen-activated protein 
kinase signaling pathway and downstream effects on cellular processes.  
Another pathway activated by β-ADRs is the PI3 kinase and protein kinase B (Akt) 
pathway.  In addition to G protein-mediated signaling, β-ADRs may also 
participate in G protein-independent signaling through β-arrestin and MAPK.  
Figure reproduced from Kum JJY, Khan ZA.  Mechanisms of propranolol action in 
infantile hemangioma.  Dermato-Endocrinology.  2015; 6:1, e979699. 
 
7 
 
1.4 Hemangioma-derived endothelial cells (HemECs) 
Exposure of endothelial cells (ECs) isolated from hemangioma specimens to 
propranolol has been shown to induce apoptosis [53].  This is evident upon 
exposure to 100 µM propranolol in the culture media [35, 53].  Previous literature 
has found significant increase in caspase-3 and -9 cleavage products, but not 
caspase-8 cleavage following propranolol exposure, suggestive of an intrinsic 
apoptotic pathway mediated by propranolol [53].  However, other studies have 
found an increase in protein and mRNA levels of caspase-8 [35], indicative of 
both intrinsic and extrinsic involvement of the apoptotic pathway.  At the mRNA 
level, it was reported that propranolol induces expression of apoptotic genes, 
such as Bax, p53, caspase-8, and cytochrome c in hemangioma ECs that may 
be responsible for its apoptotic effect [35, 53].  These studies have essentially 
examined the effect of propranolol without the addition of β-ADR stimulation.  
This may suggest a constitutively active β-ADR pathway.  A caveat worth noting 
here is that these ECs are considered to be hemangioma tumour-derived 
(hemECs).  Because there is no specific marker or cellular activity of 
hemangioma tumour ECs, it is possible that these cultures may represent a 
heterogeneous population of tumoural and non-tumoural ECs (recruited or 
angiogenic cells).  Interestingly, propranolol’s effect is not specific to hemECs, as 
it has been shown to cause apoptosis in a similar manner in other EC types as 
well including normal human dermal ECs [32, 54]. 
In addition to caspase-mediated apoptosis, propranolol may block 
phosphorylation of vascular endothelial growth factor receptor 2 (VEGFR-2) [55].  
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It was found that when hemECs were challenged with higher concentrations of 
propranolol (50 and 100 µM), the expression of vascular endothelial growth factor 
(VEGF) at the protein level was reduced in a dose-dependent manner [53, 56].  
This reduction in the level of activated VEGFR-2 and VEGF protein upon 
propranolol exposure was a critical element that affected the survivability of these 
hemECs [55, 57].  In addition, decrease in key cyclin levels and an increase in 
cell cycle inhibitor levels were observed [55].  This suggested that cell cycle 
regulation is also another mechanism involved in mediating propranolol’s 
therapeutic effect.  HemECs show a greater proportion of cells in the G1 phase 
than the S/G2 phase when treated with propranolol [32, 55].  This was further 
confirmed with decreased expression of cyclin proteins such as cyclins A1, A2, 
B2, D1, D2, D3 [32, 55], while cell cycle inhibitor proteins p15, p21, p27 [55], 
were up-regulated.   
Many studies have gone in-depth with analyzing the expression levels of the 
different β-ADR subtypes.  It has been shown that hemECs and other EC types 
express both β1- and β2-ADRs at very similar levels, but not β3 [55, 58].  Despite 
the various β-ADRs expressed, it is believed that the main mechanism of action 
of propranolol in hemECs may involve β1 and/or β2-ADR pathway.  A recent 
report has shown that ICI-118551 (selective β2-ADR antagonist) was more 
effective than metaprolol (selective β1-ADR antagonist) in inhibiting hemECs 
proliferation [59]. 
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1.5 Hemangioma-derived pericytes (HemPericytes) 
Pericytes are cells that control EC proliferation and survival by stabilizing the 
vascular wall and releasing pro-survival signals [60].  In addition, pericytes 
promote survival of ECs through vascular endothelial growth factor A (VEGF-A) 
signaling and Bcl-w [61].  It is known that addition of β-ADR agonists and cAMP 
analogues can induce relaxation of pericytes [62].  Recently, pericytes isolated 
from hemangiomas (hemPericytes) have also been tested for a potential role in 
propranolol-mediated vascular regression.  When hemPericytes were exposed to 
propranolol, epinephrine-induced relaxation was prevented [63].  Furthermore, 
the proliferative capacity of hemPericytes was reduced.  These pericytes also 
expressed β2-ADRs on their cell surface [63].  With knockdown of β2-ADR, 
hemPericytes lost epinephrine-induced relaxation and propranolol had no effect 
[63].  This suggested that β2-ADR is involved with relaxation and contractility of 
hemPericytes in response to propranolol [63].  In addition, when hemPericytes 
co-implanted with hemECs were exposed to propranolol, propranolol decreased 
the vascular volume indicative of increased vasoconstriction [63].  This may be 
suggestive of a possible mechanism by which propranolol causes increased 
constriction of the vasculature in IH to reduce the blood flow to the tumor, limiting 
its growth. 
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1.6 Hemangioma-derived stem cells (HemSCs) 
We have shown that IHs are derived from multipotential stem cells termed 
hemangioma stem cells (hemSCs) [10].  Clonally expanded hemSCs differentiate 
into ECs and produce Glut1-positive microvessels in immunodeficient mice.  
Interestingly, hemECs are unable to produce microvessels in nude mice showing 
that hemangioma initiating cells are hemSCs.  Binding of VEGF-A and vascular 
endothelial growth factor B (VEGF-B) to vascular endothelial growth factor 
receptor 1 (VEGFR-1) expressed on the surface of hemSCs has been shown to 
be required for the induction of hemSCs to EC differentiation, and for blood 
vessel formation [64].  Immunostaining of IH specimens shows co-labelling of EC 
markers and stem cell markers indicative of an immature EC phenotype in IH [13].  
Therefore, these cells represent the true cellular target to understand the 
mechanism of propranolol action in hemangiomas.   
 
1.7 Effect of propranolol in other neoplasms 
The progression of various cancers has been associated with alteration of β-ADR 
signaling pathways.  Hence, β-blockers have been proposed as therapeutic 
agents for various cancers.  Pediatric melanoma is a rare disease but its 
incidence has increased in the young population.  Melanoma is accountable for 
up to 3% of all pediatric malignancies [65].  Similar to IH, melanoma cases are 
more commonly diagnosed in Caucasian and female patients [66], and almost 
20% of malignant melanoma occurs in the head and neck region [67].  
Melanocyte stem cells (MelSCs) generate melanocytes that produce melanin-
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pigment throughout adult life.  The pathogenesis of melanoma is still subject to 
debate, but many have suggested mutations in MelSCs involving the cell cycle 
and apoptosis pathways, such as tumour protein p53 pathways, and stressors 
that increase catecholamines are involved in tumour progression [68, 69].   
The increase in norepinephrine and epinephrine primarily modulates the β-ADR 
pathways through PKA and MAPK signaling mechanisms, ultimately affecting the 
growth and progression of melanoma [70].  Additionally, increase in the 
expression of VEGF, interleukin (IL) -6 and IL-8 after catecholamine stimulation 
correlates with the aggressiveness of the tumour [70, 71].  Melanoma cells 
express both β1- and β2-receptors with β1-ADR expression being weaker 
relative to β2-ADR [68, 70]. Recently, β3-ADRs have been proposed to be 
involved in melanoma growth and vascularization [72], and the use of β-blockers 
in malignant melanoma decreased the risk of progression [73].  Although the 
exact mechanism underlying the effectiveness of these medications in reducing 
tumour progression is unknown, it has been suggested that β-blockers reduce 
angiogenic factors and metastatic progression [73].  β-blockers may inhibit 
angiogenesis by reducing VEGF activity via MAPK signaling.  In addition, β-
blockers modulate matrix metalloproteinases (MMPs) that can alter the tumour 
microenvironment involved with angiogenesis [74].  Recently, specific inhibition 
of β3-ADRs in melanoma cells was found to impair cell growth and induce 
apoptosis [72]. 
β-ADR has also been implicated in breast cancer.  Breast cancer cells express 
both β1- and β2-ADRs [75, 76], and the polymorphisms of β-ADR subtypes may 
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be associated with breast cancer susceptibility [77].  Breast cancer patients who 
received propranolol for hypertension displayed reduced metastasis and cancer 
recurrence [78].  This may be due β-ADR involvement in gene expression within 
the primary tumour [79].  Further investigation of β-ADR signaling provided 
evidence that the β-ADR pathway controls the stimulation of the arachidonic acid 
cascade [80].  In breast cancer development, arachidonic acid is a critical 
molecule that has been shown to activate mTOR (mammalian target of 
rapamycin) and increase the activity of VEGF [81].  mTOR and VEGF seem to be 
a common pathway in breast cancer and in hemECs, involving enhanced 
angiogenesis. 
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1.8 Rationale 
A number of studies have investigated the effect of propranolol on IH-derived 
endothelial cells to offer insight into the mechanisms of therapeutic effect of 
propranolol [53, 55, 58].  These studies show that propranolol causes apoptosis 
in IH endothelial cells by activating caspase-3 and also blocks other cellular 
activities including migration and tubule formation [53, 55].  This effect of 
propranolol is also exhibited by normal endothelial cells [32, 55].  We have 
shown that IH arises from multipotent stem cells [10].  Utilizing stem cell antigen 
CD133, we isolated stem cells from hemangiomas and showed that these cells 
produce hemangioma lesions in mice.  Interestingly, IH-derived endothelial cells 
(exhibiting mature endothelial phenotype as assessed by endothelial cell 
markers) fail to produce Glut1-positive microvessels [10].  This suggests that the 
cell of interest, at least in proliferating phase IH when treatments are required, is 
the hemSCs.   
It has been observed that all hemangiomas do not respond the same way to 
propranolol, as up to 20% of cases of hemangiomas regrow upon cessation of 
propranolol treatment [82].  This puzzling finding has been attributed to early 
treatment withdrawal and/or long proliferating phase of IH.  Since IHs regrow in a 
significant proportion of patients that discontinue propranolol treatment [29], it is 
possible that hemSCs, unlike hemECs and normal vascular ECs, are not 
susceptible to propranolol-induced apoptosis.   
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1.9 Hypothesis 
We hypothesize that propranolol does not cause apoptosis in hemangioma stem 
cells.  If true, this may explain why recurrence of these tumours often occurs 
following cessation of treatment. 
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Chapter 2  
2 Materials and Methods 
2.1 Infantile hemangioma specimens and immunostaining 
All studies were conducted following approval by the Research Ethics Board at 
Western University, London, Ontario, Canada.  Paraffin-embedded IH specimens 
were obtained from the Department of Pathology Archives at the London Health 
Sciences Centre (LHSC, London Ontario, Canada).  The proliferating phase was 
confirmed through medical history, physical examination, and histological 
analysis of densely packed capillaries.  In addition, all hemangioma sections 
were immunostained with Glut1 to confirm diagnosis.  Tissue sections were 
deparaffinized, hydrated, and subjected to antigen retrieval using Tris/EDTA 
buffer (10 mM Trizma-base, 1 mM EDTA, 0.05% Tween-20, pH 9.0) in 2100 
Retriever (Electron Microscopy Sciences, Hatfield, PA).   
Slides were incubated slides with mouse anti-human CD31 (1:50; M0823, Dako 
Canada, Mississauga, ON) and rabbit anti-human CD133 antibody (1:100; 
ab19898, Abcam, Cambridge, MA) for 1 hour at room temperature.  Fluorescein- 
or texas red-conjugated secondary antibodies (Vector Laboratories, Burlington, 
ON) were used for detection.  Slides were counterstained with DAPI (Vector 
Laboratories).  Images were taken using the Olympus BX-51 microscope 
(Olympus Canada In., Richmond Hill, ON) equipped with a Spot Pursuit digital 
camera (SPOT Imaging Solutions, Sterling Heights, MI).   
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2.2 Infantile hemangioma cell culture 
Proliferating IH-derived CD133+ cells (hemSCs) were provided by Dr.  Joyce 
Bischoff (Children’s Hospital Boston, Boston, MA).  We have previously 
characterized these cells through qRT-PCR, immunostaining, and cellular activity 
assays [83].  Freshly isolated human bone marrow-mesenchymal progenitor cells 
(bm-MPCs; isolated from bone marrow mononuclear preparations; 2M-125B, 
Lonza Inc., Walkersville, MD) were used as normal stem/progenitor controls.  
Neonatal human dermal microvascular endothelial cells (HDMECs; CC-2516, 
Lonza Inc.) were also used as controls.  All cells were cultured on fibronectin-
coated (FN; 1 µg/cm2, FC010-10, Millipore, Temecula, CA) plates in complete 
EBM2 media (Lonza) supplemented with 20% fetal bovine serum (Lonza), EGM-
2 SingleQuots (CC-4176, Lonza Inc.) and 1X antibiotic antimycotic media (PSF; 
Life Technologies).  Cells were cultured under identical conditions and 
experiments were performed with a minimum of 2 biological replicates (different 
IH cell preparations) and 3 technical replicates. 
2.2.1 Cell growth assay 
To determine the effect of propranolol on cellular growth and survival, we plated 
each cell type at 5000 cell/cm2 in complete EBM2 growth media (described 
above).  After 24 hours, media was removed and cells were exposed to the 
following treatments: (RS)-1-[(1-Methylethyl)amino]-3-(1-naphthalenyloxy)-2-
propanol hydrochloride (25, 50, or 100 µM Propranolol; 0624, R&D Systems, 
Minneapolis, MN); CGP 20712 dihydrochloride (10 nM CGP; 1024, Tocris 
Bioscience); ICI 118,551 hydrochloride (10 nM ICI; 0821, Tocris Bioscience); 
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nadolol (25, 50, or 100 µM; 253175, Santa Cruz); 5-carboxamidotryptamine 
maleate (200 nM or 1 μM 5-CT; 0458, Tocris Bioscience, Bristol, UK); SDZ 
21009 (200 nM or 1 μM SDZ; 1516, Tocris Bioscience);  (S)-(6-Methoxyquinolin-
4-yl)((2R,4S,8R)- 8-vinylquinuclidin-2-yl)methanol hydrochloride (1, 25, 50, or 
100 µM Quinidine; 4108, Tocris Bioscience) in fresh EBM2 media (Table 1).  
Number of live cells was determined at 24 or 72 hours using Scepter 2.0 
Automated Cell Counter (Millipore) with appropriate histogram gating setup [84, 
85].  Data were normalized to each respective control groups as multiple 
experiments were performed in various plate sizes.   
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Table 1: List of treatments used 
Name Concentration Function Source 
Propranolol 
25 µM 
50 µM 
100 µM 
β1/2-ADR antagonist 
Tocris 
(CAS 3506-09-0) 
CGP 10 nM β1-ADR antagonist 
Tocris 
(CAS 1216905-73-5) 
ICI 10 nM β2-ADR antagonist 
Tocris 
(CAS 72795-01-8) 
5-CT 
200 nM 
1 μM 
5-HTR 1/7 agonist 
Tocris 
(CAS 74885-72-6) 
SDZ 
200 nm 
1 μM 
5-HTR antagonist 
potent activity for 1A/1B 
Tocris 
(CAS 39731-05-0) 
Nadolol 
25 µM 
50 µM 
100 µM 
β1/2-ADR antagonist 
Santa Cruz 
Biotechnology 
(CAS 42200-33-9) 
Quinidine 
1 μM 
25 µM 
50 µM 
100 µM 
Class 1A antiarrhythmic 
agent (Membrane 
stabilizing agent) 
Tocris 
(CAS 56-54-2) 
  
19 
 
2.2.2 Cellular transfection 
To transfect the cells with silencing RNA, we coated 12-well plates with basal 
EBM2 media (Lonza) supplemented with 20% fetal bovine serum (Lonza), EGM-
2 SingleQuots (CC-4176, Lonza Inc.) without GA-1000 (gentamicin sulfate; CC-
4381a, Lonza) and 1X antibiotic antimycotic media (PSF; Life Technologies) 
(EBM2 antibiotic/antimycotic free media) for 30 minutes on the day of 
transfection.  The cells were transfected with either control siRNA-A (sc-37007, 
Santa Cruz, Santa Cruz, CA), β1-adrenergic receptor siRNA (sc-29580, Santa 
Cruz), or β2-adrenergic receptor siRNA (sc-39866, Santa Cruz) at a 
concentration of 200 nM.  Cells were transfected with siRNA using an 
electroporation device (Neon® Transfection System, MPK5000S, Life 
Technologies).  Transfected cells were incubated for 24 hours in 
antibiotic/antimycotic-free EBM2 media.  After 24 hours, complete EBM2 media 
was added.  After 24 or 72 hours of culture, cells were collected for total number 
of live cells and for RNA isolation.  β1- or β2-ADR knockdown was confirmed by 
qRT-PCR.  Identical protocol was used to transfect both hemSCs and HDMECs.   
 
2.3 RNA isolation, mRNA profiling & quantitative RT-PCR 
RNA was isolated using Aurum Total RNA isolation kit (Bio-Rad) or RNeasy 
Micro Plus Kit (Qiagen, Mississauga, ON).  RNA was measured using Qubit RNA 
Broad Range Assay in a Qubit Fluorometer (Life Technologies).  cDNA was then 
synthesized using iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, 
CA).  We performed gene expression analyses using RT2 Human Cell Death 
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Pathway Finder PCR arrays (PAHS-212Z; Qiagen) (Table 2).  Data was 
analyzed by CFX Manager Software using normalized (ΔΔCT) method with two 
housekeeping genes (β-actin and GAPDH were both used for normalization after 
empirically determining the expression for stability in our treatment groups). 
Various receptor levels and downstream signaling gene expression was 
assessed by qRT-PCR (Table 2,3).  Reactions consisted of 10 µL ssoFast 
Evagreen (1725200, Bio-Rad), 2 µL of both forward and reverse primers (at a 10 
µM concentration), 2 µL cDNA, and 6 µL of H2O.  Target gene mRNA data was 
normalized to β-actin (QT01680476, Qiagen).  All reactions were performed for 
40 cycles using the following temperature profiles: 95°C for 2 minutes (initial 
denaturation); and 60°C for 30 seconds (annealing and extension).  Data was 
analyzed using normalized (ΔΔCT) method or relative quantity (ΔCT). 
Adipogenesis-specific gene expression was also assessed by qRT-PCR (Table 
2).  Adipogenesis was assessed by C/EBPα (QT00203357, Qiagen) and 
PPARγ2 (sequence shown in [86]).  Target gene mRNA data was normalized to 
β-actin (QT01680476, Qiagen).  All reactions were performed for 40 cycles using 
the following temperature profiles: 95°C for 2 minutes (initial denaturation); and 
55°C for 12 seconds (annealing and extension).  Data was analyzed using 
relative quantity (ΔCT).  
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Table 2: List of primers used 
Gene Length (bp) Source (catalogue #) 
B-cell CLL/lymphoma 2 
(BCL2) 
108 Bio-Rad (qHsaCED0057245) 
Actin, beta (β actin) 104 Qiagen (QT01680476) 
Cyclin-D1 (CCND1) 96 Qiagen (QT00495285) 
CCAAT/enhancer binding 
protein alpha (C/EBPα) 
88 Qiagen (QT00203357) 
Peroxisome proliferator-
activated receptor gamma 2 
(PPARγ2) 
113 Qiagen (QT00029841) 
v-akt murine thymoma viral 
oncogene homolog 1 (AKT 1) 
138 Qiagen (QT00085379) 
v-akt murine thymoma viral 
oncogene homolog 2 (AKT 2) 
139 Qiagen (QT00085001) 
v-akt murine thymoma viral 
oncogene homolog 3 (AKT 3) 
138 Qiagen (QT00082138) 
Beta-1-adrenoceptor  
(β1-ADR) 
112 Qiagen (QT00204309) 
Beta-2-adrenoceptor  
(β2-ADR) 
136 Qiagen (QT00200011) 
Beta-3-adrenoceptor  
(β3-ADR) 
 
86 Qiagen (QT00200004) 
Plate   
RT2 Human Cell Death 
Pathway Finder PCR arrays 
 Qiagen (PAHS-212X) 
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Table 3: List of primers used in customized plate  
Gene Length (bp) Source (assay ID)  
Housekeeping gene  
Actin, beta (ACTB) 
 
62 Bio-Rad (Hs.520640) 
Adrenergic Receptors   
adrenergic, alpha-1A-, receptor 
(α1A-ADR) 
96 Bio-Rad (Hs.709175) 
adrenergic, alpha-1B-, receptor 
(α1B-ADR) 
112 Bio-Rad (Hs.368632) 
adrenergic, alpha-1D-, receptor 
(α1D-ADR) 
140 Bio-Rad (Hs.557) 
adrenergic, alpha-2A-, receptor 
(α2A-ADR) 
102 Bio-Rad (Hs.249159) 
adrenergic, alpha-2B-, receptor 
(α2B-ADR) 
119 Bio-Rad (Hs.247686) 
adrenergic, alpha-2C-, receptor 
(α2C-ADR) 
145 Bio-Rad (Hs.123022) 
adrenergic, beta-1-, receptor  
(β1-ADR) 
94 Bio-Rad (Hs.99913) 
adrenergic, beta-2-, receptor  
(β2-ADR) 
82 Bio-Rad (Hs.2551) 
adrenergic, beta-3-, receptor  
(β3-ADR) 
 
77 Bio-Rad (Hs.2549) 
Downstream signaling molecules  
v-akt murine thymoma viral 
oncogene homolog 1 (AKT1) 
143 Bio-Rad (Hs.525622) 
v-akt murine thymoma viral 
oncogene homolog 2 (AKT2) 
71 Bio-Rad (Hs.631535) 
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v-akt murine thymoma viral 
oncogene homolog 3 (AKT3) 
97 Bio-Rad (Hs.498292) 
B-cell CLL/lymphoma 2 (BCL2) 108 Bio-Rad (Hs.150749) 
Cyclin-D1 (CCND1) 143 Bio-Rad (Hs.523852) 
cAMP responsive element 
binding protein 1 (CREB1) 
76 Bio-Rad (Hs.516646) 
protein kinase, cAMP-dependent, 
catalytic, alpha (PRKACA) 
74 Bio-Rad (Hs.631630) 
protein kinase, cAMP-dependent, 
catalytic, beta (PRKACB) 
88 Bio-Rad (Hs.487325) 
protein kinase, cAMP-dependent, 
catalytic, gamma (PRKACG) 
 
84 Bio-Rad (Hs.158029) 
5-hydroxytryptamine (Serotonin) receptors  
5-hydroxytryptamine (serotonin) 
receptor 1A (HTR1A) 
86 Bio-Rad (Hs.247940) 
5-hydroxytryptamine (serotonin) 
receptor 1B (HTR1B) 
108 Bio-Rad (Hs.123016) 
5-hydroxytryptamine (serotonin) 
receptor 1D (HTR1D) 
89 Bio-Rad (Hs.121482) 
5-hydroxytryptamine (serotonin) 
receptor 1E (HTR1E) 
99 Bio-Rad (Hs.1611) 
5-hydroxytryptamine (serotonin) 
receptor 1F (HTR1F) 
73 Bio-Rad (Hs.248136) 
5-hydroxytryptamine (serotonin) 
receptor 2A (HTR2A) 
63 Bio-Rad (Hs.654586) 
5-hydroxytryptamine (serotonin) 
receptor 2B (HTR2B) 
81 Bio-Rad (Hs.421649) 
5-hydroxytryptamine (serotonin) 
receptor 2C (HTR2C) 
 
144 Bio-Rad (Hs.149037) 
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5-hydroxytryptamine (serotonin) 
receptor 3A (HTR3A) 
140 Bio-Rad (Hs.413899) 
5-hydroxytryptamine (serotonin) 
receptor 4 (HTR4) 
97 Bio-Rad (Hs.483773) 
5-hydroxytryptamine (serotonin) 
receptor 5A (HTR5A) 
105 Bio-Rad (Hs.65791) 
5-hydroxytryptamine (serotonin) 
receptor 6 (HTR6) 
150 Bio-Rad (Hs.22180) 
5-hydroxytryptamine (serotonin) 
receptor 7 (HTR7) 
142 Bio-Rad (Hs.73739) 
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2.4 Protein quantification 
Total proteins from the cultured cells were extracted using Cell Extraction Buffer 
(Life Technologies) with complete protease inhibitor cocktail (Roche Diagnostics, 
Laval, Quebec).  Proteins were measured by BCA Protein Assay Reagent 
(Pierce BCA Protein Assay Kit, Thermo Scientific, Rockford, IL) and equal 
amounts were used for various protein measurements.   
2.4.1 Caspase-3 and Cyclin-D1 measurements 
To measure activated caspase-3, caspase-3 (active) Human ELISA kit (Life 
Technologies) was used.  Data were collected using Thermo Scientific Multiskan 
FC Microplate Photometer (Thermo Scientific), measuring absorbance at 450nm.  
Cyclin-D1 level was measured similarly using PathScan Total Cyclin-D1 
Sandwich ELISA kit (Cell Signaling Technology Inc., Danvers, MA).   
2.4.2 Protein Kinase A Activity measurement 
To quantify Protein kinase A (PKA) activity, PKA Kinase Activity kit (Abcam) was 
used.  Data were collected using Thermo Scientific Multiskan FC Microplate 
Photometer (Thermo Scientific), measuring absorbance at 450nm.   
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2.5 Adipogenic Differentiation 
To induce adipogenic differentiation, hemSCs were seeded at a density of 
40,000 cells/cm2 in StemPro Adipogenesis differentiation media (Adipo media; 
Life Technologies).  Control media consisted of Dulbecco's Modified Eagle 
Medium supplemented with 10% FBS.  Media was changed every other day.  
RNA was isolated from cells after 7 days to perform qRT-PCR for β-adrenergic 
receptor expression.  To determine whether cell growth/proliferation may alter 
adipogenesis, we pretreated hemSCs with 10 μg/mL mitomycin C (MitoC; Sigma 
Aldrich, Oakville, ON) for 2 hours.  Cells were then washed, resuspended, and 
plated at 40,000 cells/cm2 in adipogenesis media.  RNA was isolated at day 4 to 
assay for C/EBPα and PPARγ2 levels (transcription factors essential for 
adipogenic differentiation). 
 
2.6 Statistical Analysis 
The data were expressed as means ± SEM.  Where appropriate, student’s 
unpaired t-tests or analysis of variance (ANOVA) were performed.  P values < 
0.05 were considered statistically significant. 
27 
 
Chapter 3  
3 Results 
3.1 Atypical phenotype of hemangioma endothelium 
Previous studies have investigated the effect of propranolol on IH-derived 
endothelial cells to offer insight into its mechanism of therapeutic effect [53, 55, 
58].  However, we have shown that CD133-selected cells from human IH initiate 
hemangioma lesions in mice, producing Glut1-positive microvessels [10].  This 
suggests that the mechanism of therapeutic effect of propranolol needs to be 
investigated on hemSCs.  Therefore, we performed immunostaining for CD133 to 
probe for microvessels that are lined by CD133-expressing cells (hemangioma 
vessels).  Results from two proliferating IH specimens show that all microvessels 
within IH tissues are immunoreactive to CD133 (Figure 2).  This suggested that 
for understanding the effect of propranolol, CD133-selected hemSCs are 
essential.   
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Figure 2: Hemangioma vessels are lined with CD133-positive cells. 
Proliferating hemangioma specimens were characterized through 
immunostaining.  Hemangioma specimens were double labeled for CD31 
(endothelial cell marker; red) and CD133 (stem cell antigen; green).  4′,6-
Diamidino-2-phenylindole (blue) was used as counterstain.  Staining illustrates 
complete co-localization of CD31 and CD133 in both proliferating hemangioma 
specimens (images were taken at magnification of ×20; insets illustrate high 
magnification; bar = 200 μm).  Human skin and placenta were used as negative 
and positive controls respectively for CD133 (Data not shown). 
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3.2 Propranolol inhibits hemSCs growth 
Our next objective was to determine the effect of propranolol on the growth of 
hemSCs.  We cultured the cells with 25, 50, or 100 µM propranolol and assayed 
for live cell number at both 24 and 72 hours.  We chose these concentrations 
based on previous studies that have observed significant differences in IH 
endothelial cells [32, 55].  Furthermore, propranolol has been shown to have 
immediate effects in inhibiting cell viability at 24 hours [53].  Interestingly, no 
significant changes to cell number were observed in hemSCs at 24 hours (Figure 
3A).  At 72 hours, bm-MPCs and HDMECs showed significant reductions in cell 
number at all concentrations of propranolol when compared to control (Figure 
3B).  In contrast, a proliferative effect was observed when hemSCs were treated 
with 25 µM propranolol and a reduction in live cell number with 100 µM 
propranolol (Figure 3B).   
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Figure 3: 100 μM propranolol reduces hemSCs growth after 72 hours. 
Live cell number after (A) 24 hours and (B) 72 hours of treatment with different 
concentrations of propranolol.  Propranolol treatment at 100 μM reduced number 
of cells compared with control after 72 hours. (*P < 0.05 compared with 
respective control). 
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3.3 Reduced cell number following propranolol treatment is not due to 
apoptosis in hemSCs 
As the cell number decreased significantly for all cell types when cultured in 100 
µM propranolol (at 72 hours), we examined whether this was due to apoptosis.  
Therefore, cells treated with propranolol were assayed for active caspase-3.  
Caspase-3 is the most frequently activated death protease and has been shown 
to play a role in inducing endothelial cell apoptosis upon propranolol treatment 
[53, 55].  Unexpectedly, hemSCs treated with 100 µM propranolol showed a 
significant reduction in the level of active caspase-3.  This suggested that in 
hemSCs, the reduction in cell number might be due to inhibited cell growth and 
not apoptosis.  bm-MPCs did not show a significant difference upon propranolol 
treatment as caspase-3 levels remained unchanged (Figure 4A).  On the other 
side of the spectrum, propranolol-treated HDMECs showed a significant increase 
in the level of activated caspase-3 as expected.  These data demonstrate that 
propranolol treatment induces apoptosis in HDMECs, whereas the decrease in 
cell number in hemSCs and possibly bm-MPCs is mediated by a reduction in cell 
growth.   
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3.4 Propranolol halts cell cycle progression but does not induce 
apoptosis in hemSCs 
We examined the effect of propranolol on cyclin-D1 level.  Cyclin-D1 is a key 
regulator in the progression from G1/S phase and has recently been shown to be 
maintained in G2 phase [87].  Recent studies have shown that propranolol 
reduces cyclin-D1 in a time-dependent manner in endothelial cells [32].  
Surprised by previous experimental findings, we wanted to determine if 
propranolol reduces cyclin-D1 in hemSCs.  Our results do show significantly 
reduced cyclin-D1 in hemSCs upon propranolol treatment (Figure 4B).  Similarly, 
bm-MPCs and HDMECs cyclin-D1 levels were also significantly reduced (Figure 
4B).  The greatest change in cyclin-D1 was seen in bm-MPCs which may explain 
the reduced cell number seen earlier.  These results suggest that propranolol 
inhibits cell cycle progression in all cell types by decreasing level of cyclin-D1. 
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Figure 4: Propranolol inhibits caspase-3-mediated apoptosis in hemSCs. 
Levels of (A) active caspase-3 and (B) cyclin-D1 in hemSCs, bm-MPCs, and 
HDMECs following 100 μM propranolol treatment for 72 hours by ELISA. 
(*P < 0.05 compared with respective control). 
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3.5 Propranolol induces anti-apoptotic pathways in hemSCs 
In order to understand the possible mechanism by which propranolol induces 
apoptosis in endothelial cells but not hemSCs, we used quantitative RT-PCR to 
profile for genes important in the central mechanisms of cellular death.  We used 
a Human Cell Death Pathway Finder PCR Array (Qiagen; see Methods for 
details) which comprises 84 key genes important for cell survival and apoptosis.  
HemSCs, bm-MPCs, and HDMECs were cultured in normal growth media or in 
media containing different concentrations of propranolol for 72 hours.  Using this 
PCR-based array, we found that propranolol significantly induces various anti-
apoptotic pathways in hemSCs and normal bm-MPCs (Figure 5).  These included 
Akt (also known as protein kinase B; induced 31.2x in hemSCs, 7.58x bm-MPC), 
Bcl2 (295.9 x in hemSCs, 143.2x bm-MPC)/Bcl2A (23.4x in hemSCs, 10.9x in 
bm-MPC), and insulin-like growth factor receptor-1 (IGFR1, 53.6x in hemSCs, 
9.2x in bm-MPC).  In contrast, we did not observe any alteration of these anti-
apoptotic pathways in HDMECs (Figure 5).   
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Figure 5: Propranolol induces anti-apoptotic signaling pathways in 
hemSCs. 
Propranolol induced the expression of anti-apoptotic genes in hemSCs and bm-
MPCs but not in HDMECs. (mRNA levels were measured using RT2 Cell Death 
Pathway Finder (Qiagen, Mississauga, ON) and normalized to β-actin and 
glyceraldehyde 3-phosphate dehydrogenase levels; red dashed lines highlight 
100 μM propranolol groups; graph shown are representative of multiple PCR 
arrays). 
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3.6 β2 and β3 are the predominant β-ADRs in hemSCs  
We next assayed for β-ADR expression in hemSCs and compared the levels to 
mature endothelial cells.  Our results show that hemSCs express both β2- and 
β3-ADRs (Figure 6).  β1-ADR mRNA levels, although detectable, were 
significantly lower.  Interestingly, we found that bm-MPCs share β-ADR profile 
with hemSCs.  Mature endothelial cells (human microvascular endothelial cells; 
HDMECs) on the other hand exhibited higher level of β1-ADR expression (Figure 
6).  No significant differences were found in the level of β2- or β3-ADRs between 
endothelial cells, hemSCs, and bm-MPCs.   
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Figure 6: β2/3-ADRs are predominantly expressed in hemSCs. 
qRT-PCR analysis of β-ADRs in hemSCs, bm-MPCs, and HDMECs were 
determined by real-time quantitative reverse-transcriptase PCR. (Data 
normalized to β-actin; *P < 0.05 compared with β1-ADR mRNA levels in hemSCs 
and bm-MPCs; †P < 0.05 compared with β2- and β3-ADR mRNA levels).  RNA 
was isolated from cells cultured in Endothelial Basal Media-2 (EBM2) under 
identical conditions.  The specificity of the amplification was determined by 
melting curve analysis (Appendix A). 
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3.7 β-ADR downstream signaling molecules are detectable, but too low 
to quantify in hemSCs 
To ensure the effects we observed upon propranolol exposure were through β-
ADR inhibition, we investigated the change in key downstream signaling 
molecules upon propranolol exposure.  PKA is an important mediator for cellular 
processes where its function depends on cAMP.  Although we have observed a 
linear standard curve for active PKA standards in our study (Figure 7, Table 4), 
PKA activity upon 25 and 100 µM propranolol was below the detection limit in 
both hemSCs and HDMECs.  Even with the addition of 20 ng of exogenous 
active PKA in hemSC and HDMEC protein samples, the amount of active PKA 
remained below the quantitative limit (Table 5).   
 
 
Figure 7: Linear standard curve for active PKA standards.   
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Table 4: PKA activity in purified PKA standards 
PKA Standards 
(ng) 
Active PKA 
amount (ng) 
0 0 
9.375 9.48 
18.75 18.70 
 
Table 5: PKA activity in hemSCs and HDMECs 
Cell type Treatment 
Active PKA amount (ng) 
with addition of exogenous 
20 ng of active PKA 
HemSCs 
Control 1.93 
25 µM Propranolol 1.93 
100 µM Propranolol 2.03 
HDMECs 
Control 1.13 
25 µM Propranolol 1.32 
100 µM Propranolol 1.50 
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3.8 Specific β-ADR antagonist does not affect hemSCs 
As β1-ADR was predominantly expressed in the well-differentiated endothelial 
cells, we questioned whether specific β1-ADR antagonists can mimic propranolol.  
We cultured the cells with 10 nM CGP (β1-selective blocker) and/or ICI (β2-
selective blocker) and assayed for live cell number after 72 hours.  If propranolol 
is acting through β1-receptor that is predominantly expressed in endothelial cells, 
then we would expect decreased growth in this particular cell type with CGP.  
Indeed, our results show that 10 nM of CGP, but not ICI, significantly decrease 
cell number when compared with control (Figure 8).  When CGP and ICI are 
combined to represent propranolol’s non-selective binding characteristic, 
HDMEC number is also significantly reduced (Figure 8).  In contrast, no 
significant changes to live cell number were observed in hemSCs with all 
treatments using specific β-ADR antagonists (Figure 8).  This suggests that β-
ADR signaling pathway may not be involved in hemSCs. 
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Figure 8: Specific β1- and β2-ADR antagonist does not affect growth of 
hemSCs. 
Live cell number after 72 hours of treatment with selective β-ADR antagonists.  
β1- and β2-selective blockers did not affect the cell number compared to control 
in hemSCs. (*P < 0.05 compared to respective control). 
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3.9 Specific β-ADR silencing does not affect hemSCs growth 
To rule out propranolol’s β-ADR-dependent mechanism of action in hemSCs, we 
transfected hemSCs with specific β-ADR silencing RNA (siRNA) in complete 
growth media with or without 100 µM propranolol.  Similar to specific β-ADR 
antagonist use, the growth of hemSCs was not affected upon knockdown of β1- 
and β2-ADR (Figure 9A).  However, control and β1 siRNA-transfected hemSCs 
exposed to propranolol significantly reduced cell growth.  This was not seen with 
β2 siRNA-transfected hemSCs cultured in propranolol media (Figure 9A). 
In contrast, β-ADR knockdown significantly decreased HDMECs cellular growth 
(Figure 9A).  Specific β1 siRNA-transfected HDMECs cultured with propranolol 
significantly reduced cell number compared to β1 knockdown in complete growth 
media (Figure 9A).  Interestingly, β1-ADR knockdown HDMECs cultured with 
propranolol significantly increased growth when compared to control transfection 
with propranolol (Figure 9A).  Our findings indicate live cell number is affected in 
HDMECs with β-ADR knockdown, but not hemSCs. 
Transfection efficiency was confirmed by qRT-PCR.  We were able to achieve 
greater than 80% suppression of β2-ADR in hemSCs and HDMECs (Figure 
9B,C), and greater than 70% suppression of β1-ADR in HDMECs (Figure 9C). 
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Figure 9: Specific β1- and β2-ADR siRNA does not affect growth of hemSCs. 
Transfecting hemSCs with β1- and β2-ADR siRNA (A) did not affect growth, 
unlike HDMECs. (*P < 0.05 as compared to respective control; †P < 0.05 as 
compared to respective β-siRNA; γP < 0.05 as compared to respective control 
siRNA with propranolol).  (B,C) Knockdown efficiency was measured through β-
ADR mRNA levels.  β2-ADR knockdown efficiency was greater than 80% in both 
cell types.  β1-ADR knockdown efficiency was greater than 70% in HDMECs.  
(*P < 0.05 as compared to respective control). 
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3.10 5-HTR7 levels are significantly high in hemSCs 
To investigate β-ADR-independent mechanism of propranolol, we have profiled 
various ADRs and downstream signaling molecules.  We also measured the 
expression of 5-HTRs to which propranolol has been shown to bind [88].  
Interestingly, all of α- and β-ADR subtypes were significantly lower in hemSCs 
when compared to HDMECs (Figure 10A).  As well, majority of downstream 
signaling molecules were lower in level in hemSCs, except Bcl2 (Figure 10B).  
Similarly, many 5-HTRs were significantly lower in hemSCs, except 5-HTR7 
(Figure 11).  This hinted to us that propranolol may mediate its effects in hemSCs 
through 5-HTR7. 
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Figure 10: Low expression of α-ADR, β-ADR, and downstream signaling 
molecules in hemSCs. 
Gene profiling assay was performed to observe the mRNA levels of (A) α- and β-
ADRs and (B) downstream signaling molecules. (*P < 0.05 compared to 
HDMECs). 
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Figure 11: 5-HTR7 is highly expressed in hemSCs. 
Gene profiling assay was performed to observe the mRNA levels of 5-HTRs.  
(*P < 0.05 compared to HDMECs). 
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3.11 Serotonin agonist decreases hemSCs growth 
Previous literature has reported that propranolol can interact with 5-HTRs 
(serotonin receptors) [88].  Therefore, we explored the possibility that the 
reduction in cellular growth upon propranolol exposure in hemSCs is mediated 
through 5-HTR pathway.  Since it is not known whether binding of propranolol to 
5-HTRs leads to activation or inhibition, we first tested hemSCs with a selective 
5-HTR1/7 agonist, 5-CT, at various concentrations.  Interestingly, both 
concentrations of 5-CT significantly reduced live cell number after 72 hours, 
similar to propranolol.  If propranolol affected the hemSCs through 5-HTR 
pathway, then we would expect no significant difference when we combine 
propranolol with 5-HTR antagonist to eliminate propranolol’s effect.  Indeed, 
when we combine SDZ with propranolol, the cell number is normalized to control 
levels (Figure 12A).  Surprisingly, 5-CT at 200 nM had no significant effect on 
HDMECs, unlike hemSCs (Figure 12B).  This suggests that the two cell types 
may exhibit different cellular signaling pathways upon propranolol exposure.   
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Figure 12: 5-CT mimics the effect of propranolol in hemSCs growth. 
Live cell number after 72 hours of treatment with (A) 5-CT (5-HTR agonist) and 
combination of propranolol with SDZ (5-HTR antagonist) in hemSCs and (B) 5-
CT in hemSCs and HDMECs. (*P < 0.05 compared to respective control). 
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3.12 Propranolol-induced altered differentiation in hemSCs 
While our studies were underway, a report showed that presence of propranolol 
in adipogenic differentiation media increased the differentiation level in hemSCs 
as compared to cells in adipogenic media alone [34].  Higher levels of C/EBPβ 
and δ were found at day 4.  Interestingly, when the cells were maintained in the 
differentiation media supplemented with propranolol for 7 days, significant cell 
death was observed.  This is in contrast to our observations in normal growth 
media where a significant reduction in cell number is evident without apoptosis.  
Therefore, we explored the possibility that this enhanced adipogenic 
differentiation with propranolol is mediated through cell growth regulation.  To 
test this idea, we treated hemSCs with mitomycin C to inhibit proliferation and 
tested for C/EBP expression.  Our results show that C/EBPα was significantly 
higher when mitomycin C-treated hemSCs were exposed to adipogenic 
differentiation media for 4 days (Figure 13A).  No change was observed in 
PPARγ2 levels.  C/EBPα is a critical transcription factor in adipogenesis and 
enhanced levels suggest that inhibition of cell proliferation increases the 
differentiation capacity of hemSCs and this may be the mechanism underlying 
propranolol’s effect.  We then assayed for β-ADR expression and show here that 
adipogenesis is associated with significantly higher levels of all three ADRs 
(Figure 13B).  Therefore, cell death in adipogenic media supplemented with 
propranolol [34] might be due to increased expression of β-ADRs, which 
accompanies hemSCs differentiation. 
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Figure 13: Growth inhibition enhances adipogenesis. 
Effect of mitomycin C treatment on adipogenic differentiation (A) in hemSCs at 
day 4. (*P < 0.05 compared with control media; †P < 0.05 compared with 
adipogenic differentiation media without mitomycin C treatment).  (B) Induction of 
β-ADRs following adipogenic differentiation in hemSCs at day 7. (*P < 0.05 
compared with control media). 
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3.13 β-ADR levels change with propranolol exposure 
Changes in β-ADR expression upon hemSC differentiation prompted us to 
assess the changes in receptor profile in the presence of propranolol.  Therefore, 
we measured the level of β-ADR mRNA upon 100 µM propranolol exposure after 
72 hours.  In contrast to what we had expected based on Figure 13 (increase in 
β-ADR to increase susceptibility of hemSCs for cell death/cell cycle inhibition), 
hemSCs significantly decreased β2-receptor level after propranolol exposure 
(Figure 14A).  Furthermore, only β1-ADR level significantly increased upon 
propranolol challenge in HDMECs, whereas β2-ADR level did not significantly 
differ (Figure 14B).  Our findings indicate that the apoptosis of HDMECs with 
propranolol media may be due to the increase in β1-ADR (Figure 14B).  In 
addition, our observations indicate that propranolol changes the receptor profile 
of both cells differently, which may explain why a difference in response is 
observed. 
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Figure 14: Propranolol alters level of β-ADRs. 
Effect of propranolol exposure on β-ADR mRNA levels (A) in hemSCs and (B) 
HDMECs after 72 hours. (*P < 0.05 compared to respective control). 
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3.14 Nadolol inhibits hemSCs growth 
There have been indications that propranolol can cause central nervous system-
related side effects due to its lipophilic properties [89].  Therefore, we utilized 
nadolol, a non-selective β-ADR antagonist that is hydrophilic.  It has also been 
suggested that due to its inability to cross blood brain barrier, use of nadolol may 
be a safer treatment alternative.  We cultured the cells with 25, 50, or 100 μM 
nadolol and measured cell number at 72 hours.  Interestingly, 25 and 100 μM 
nadolol significantly reduced hemSC number when compared to control (Figure 
15).  In HDMECs, only at 100 μM was there a significant decrease in cell number, 
suggesting that nadolol may have its effect in our cell types through an 
alternative pathway, different from propranolol’s mechanism. 
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Figure 15: Nadolol decreases growth of hemSCs. 
Live cell number after 72 hours of treatment of hemSCs and HDMECs with 
different concentrations of nadolol.  Nadolol at 25 μM reduced hemSC number, 
while 100 μM reduced both hemSCs and HDMECs compared to respective 
controls. (*P < 0.05 compared to respective control). 
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3.15 Quinidine decreases hemSCs growth 
Propranolol has been observed to have membrane stabilizing effects [90].  
Hence, we wanted to examine whether this property mediates the effect of 
propranolol.  To investigate whether propranolol’s effect in hemSCs is through 
stabilizing the membrane, we exposed hemSCs to 1, 25, 50, or 100 μM quinidine, 
a membrane stabilizing agent.  Surprisingly, at the lowest concentration of 
quinidine we used, 1 μM, there was a significant increase in hemSCs growth; 
however, at high concentration of 100 μM, significant reduction of hemSCs 
growth was observed (Figure 16).  Surprisingly, HDMECs were unaffected 
across the various concentrations of quinidine.  Our findings indicate that 
propranolol may mediate its effects in hemSCs through stabilizing the membrane. 
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Figure 16: Quinidine affects hemSCs growth. 
Live cell number after 72 hours of treatment with different concentrations of 
quinidine.  Quinidine treatment at 100 μM reduced number of hemSCs compared 
to control. (*P < 0.05 compared to respective control). 
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Chapter 4  
4 Discussion & Future direction 
4.1 Discussion 
Propranolol is a widely used treatment for IH; however, the mechanism of 
therapeutic effect is still unknown.  In addition, some IH regrow after stopping 
propranolol treatment [29, 30, 91].  In the present study, we have demonstrated 
that proliferating hemangioma specimens are atypical in nature as IH 
microvessels express endothelial (CD31) and stem cell (CD133) markers (Figure 
2).  We have also shown that propranolol does not induce apoptosis in CD133-
expressing hemSCs, as seen in mature/differentiated endothelial cells (Figure 
4A).  This suggests that the direct effect of propranolol in IHs may be through 
modulating mature endothelial cells and angiogenesis.  The mechanism by which 
hemSCs and possibly normal progenitor cells (modeled here by bm-MPCs) 
escape apoptosis may include induction of anti-apoptotic pathways, a novel 
mechanism we have observed (Figure 5).  We found Akt, Bcl2/Bcl2A, and IGFR1 
to be significantly induced in hemSCs and bm-MPCs.  Akt induction is of 
particular importance here as this pro-survival kinase counteracts caspase-3 
activity [92-94].  Bcl2 downregulation has been shown to increase caspase-3 in 
breast cancer cells [95].  Furthermore, Bcl2A mediates anti-apoptotic effects of 
fibroblast growth factor in chrondogenic progenitor-like cell line [96].  Therefore, 
these pathways may be involved in reducing/counteracting caspase-3 activity in 
hemSCs that is not evident in mature endothelial cells. 
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Another interesting finding of this study is that hemSCs predominantly express 
β2- and β3-ADRs (Figure 6).  β1-ADR levels are almost ten-fold lower.  Vascular 
endothelial cells, on the other hand, express significantly high level of β1-
receptor compared to β2/3.  These findings suggest that the differential effect of 
propranolol in hemSCs and endothelial cells may be due to distinct roles of β-
ADR subtypes.  Studies have shown that β1- and β2-ADR have opposing effects 
on regulating apoptosis [97-99].  For example, Communal et al. have shown that 
activation of β1-receptors on cardiac myocytes induces apoptosis, whereas β2-
ADR activation opposes cell death [97].  Although this study involved activation 
of β-ADR and not antagonism, the concept of a distinct, receptor subtype-specific 
role is pertinent here.  Moreover, Panjala et al. have demonstrated that β1-ADR 
knockout mice exhibit increased formation of degenerate capillaries in retina 
[100].  These are interesting findings because retinal endothelial cells express 
β1-ADR but not β2 [101].  Also associated with acellular capillaries in the retina 
in knockout mice were increased level of cleaved caspase-3.  Based on our data, 
we suggest that antagonizing β1-receptor in IH endothelial cells is associated 
with cell death while β2 may be involved in cell cycle regulation (Figure 17).  We 
know that hemSCs predominantly express β2- and β3-receptors and show 
almost 10-fold lower β1-level (Figure 6).  bm-MPCs showed a similar response to 
propranolol in cellular activity and molecular alterations, and share the β-ADR 
profile with hemSCs (Figure 5,6).   
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Figure 17: Proposed mechanism of therapeutic effect of propranolol. 
Schematic illustrating the proposed mechanism of propranolol action on hemSCs 
and mature endothelial cells.  (A) Diagram illustrating the penetrance of apoptotic 
effect of propranolol in hemangioma regression.  (B) Propranolol leads to 
apoptosis in endothelial cells and other mature cell types, including adipocytes, 
through alteration of β1-ADR signaling.  Engagement of β2- (and possibly β3-) 
ADRs in ECs leads to cell cycle arrest and growth inhibition (potentially through 
decreasing cyclin-D1).  Propranolol may also activate of 5-HTRs in hemSCs.   
(? denotes unclear mechanism through 5-HTR pathway).   
Figure modified from Kum JJY, Khan ZA.  Propranolol inhibits growth of hemangioma-
initiating cells but does not induce apoptosis.  Pediatric Research.  75:381-8. 
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A recent report by Ji et al. have shown that ICI-118551 (a selective β2-ADR 
antagonist) was more effective than metaprolol (selective β1-antagonist) in 
inhibiting hemECs proliferation [59].  However, our data suggests the opposite.  
β1-antagonist decreases cell growth, whereas β2-antagonist had no effect in 
HDMECs (Figure 8).  When β1 and β2 specific antagonists were given 
simultaneously, it had less of an impact on the growth compared with β1-
antagonist alone (Figure 8).  As mentioned earlier, a similar phenomenon has 
been reported in cardiac myocytes where β1-receptors induce apoptosis and β2-
ADR activation opposes cell death [102].  Our findings indicate that the key 
mediator in promoting apoptosis in mature endothelial cells is β1-ADRs.   
To ensure the inhibition of β-ADR with propranolol in our model system, we 
measured for the downstream signaling molecule, PKA.  Previous studies have 
shown that pre-treatment with β-agonist followed by β-antagonist can decrease 
cAMP levels in a dose-dependent manner [58].  However, our study suggests 
that without exogenously activating the β-ADR system, the cells do not exhibit 
sufficient β-ADR downstream signaling (Figure 8).  We transfected our cells with 
β-ADR siRNA to determine whether propranolol mediates its effects directly 
through modulating β-ADR pathway.  Interestingly, knocking down β-ADRs in 
HDMECs significantly reduced cell growth that was not evident in hemSCs 
(Figure 9A).  These findings indicate that propranolol inhibits β-ADRs in HDMECs.  
Another unique finding is that there was an increase in cell number with β1-
siRNA transfection under propranolol exposure when compared with control 
siRNA with propranolol (Figure 9A).  When β1-ADR is knocked down in HDMECs, 
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there may not be sufficient levels of β1-ADR for propranolol to inhibit, relieving 
the apoptotic effect observed in control transfection with propranolol.  This 
highlights β-ADR-dependent mechanism of propranolol in HDMECs.  In contrast, 
hemSCs are not affected upon transfection with β-ADR siRNA alone (Figure 9A).  
Our findings indicate that propranolol may mediate its effect through a β-ADR-
independent pathway in hemSCs. 
To investigate β-ADR-independent mechanism of propranolol in hemSCs, we 
have performed a receptor profiling assay.  All α- and β-ADRs and majority of 5-
HTRs in hemSCs were significantly lower compared to HDMECs (Figure 10A, 
Figure 11).  However, 5-HTR7 expression was almost 40 times more abundant 
(Figure 11).  This was a unique finding in our study as it suggests that 
propranolol may be working through this receptor pathway.  Previous studies 
have suggested that propranolol may bind to 5-HTRs with substantial affinity [102, 
103].  There is also experimental evidence that propranolol acts as a 5-HT1A 
antagonist and a 5-HT1B agonist in the rat cortex [104].  Treatment with 
propranolol also inhibited basal cAMP and steroidogenesis in rat leydig cells, with 
effects evident at 0.1 µM [103].  Based on the data from previous studies and our 
receptor profile data, we examined whether activating or inhibiting 5-HTRs would 
mimic propranolol’s effect.  We found that 5-HTR 1/7 agonist, 5-CT, can 
significantly reduce hemSCs growth (Figure 12A,B).  Since 5-CT mimicked 
propranolol, we tested hemSCs growth in the presence of propranolol and 5-HT 
antagonist, SDZ.  If propranolol’s mechanism of action is through activating 5-
HTRs, exposing the cells with SDZ simultaneously will normalize the effect of 
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propranolol.  Indeed, this is what we have observed.  With the same 
concentration of 5-CT used for SDZ and simultaneously exposing hemSCs to 
propranolol, we were able to bring hemSCs growth to control levels (Figure 12A).  
Therefore, 5-HT pathway may in part be involved with propranolol’s effect in 
hemSCs. 
Wong et al. have shown that propranolol enhances adipogenesis in hemSCs 
[34].  Specifically, presence of propranolol in adipogenic media initially caused 
differentiation of hemSCs but significant cell death at day 7 [34], which is the 
typical in vitro time for full functional adipocyte differentiation.  We reasoned that 
the initial effect of propranolol might be mediated through cell cycle disruption.  
To test this possibility, we treated hemSCs with mitomycin-C before exposing the 
cells the adipogenic differentiation media.  We noted that mitomycin-C treated 
cells had significantly higher levels of C/EBPα induction (Figure 13A), suggesting 
that enhanced adipogenesis in hemSCs may be related to a change in the 
differentiation timeline (reduced growth and earlier differentiation).  We also 
tested whether adipogenesis itself alters β-ADR expression in hemSCs, thereby 
making cells more sensitive to propranolol’s direct effect through β-ADR.  Indeed, 
differentiation of hemSCs significantly increased the expression of all β-ADR 
subtypes including β1 (29.47-fold increase as reported in our study) (Figure 13B).  
IH ends its continuous developmental phase when adipocytes replace majority of 
the tumour lesion.  Yu et al. first reported presence of cells with adipogenic 
differentiation potential in proliferating phase IH [105].  Culturing hemSCs in the 
presence of propranolol enhances adipogenesis and this may offer another 
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possible mechanism of the beneficial effects of propranolol in IH resolution.  
Furthermore, continuous culture of hemSCs in adipogenic differentiation media 
supplemented with propranolol causes cell death [34].  These results suggested 
that propranolol treatment accelerated the dysregulated differentiation process in 
hemSCs that ultimately resulted in increased apoptosis of adipocytes derived 
from hemSCs [34].  It is possible that differentiation of hemSCs causes a shift in 
β-ADR expression profile and an increase in β1-ADR which may induce 
apoptosis.   
It has been noted that propranolol causes more central nervous system-related 
side effects than hydrophilic β-blockers as it can cross the blood-brain barrier [89].  
Therefore, we wanted to determine whether nadolol, a hydrophilic non-selective 
β-blocker, can have similar effects as propranolol in hemSCs.  Nadolol may be 
used as a safer alternative as it does not cross the blood-brain barrier and have 
little myocardial effect, unlike propranolol [106, 107].  Interestingly, hemSCs 
growth was significantly reduced at 25 and 100 µM nadolol.  A significant 
reduction of HDMECs was also evident but only at 100 µM nadolol treatment 
(Figure 15).  Clinically, it has been shown that nadolol effects are more favorable 
compared to propranolol-use after 24 weeks with similar doses administered 
[108].  These findings suggest that other β-blockers can offer another therapeutic 
option; however, further studies need to be performed to understand the 
mechanism of how these various β-blockers may be regressing IH. 
Previous studies have observed that propranolol can act as a membrane 
stabilizing agent [90, 109].  To determine whether propranolol’s effect was 
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mediated through receptors expressed on the cell surface or indirectly by 
stabilizing the cell membrane, we have treated the cells with quinidine, a 
membrane stabilizing agent that can block sodium and potassium channels.  
Interestingly, it has been noted that 100 µM quinidine can inhibit proliferation and 
induce apoptosis by increasing caspase-3 and -9 in human glioma U86-MG cells 
[110].  Surprisingly, at 1 µM quinidine, there was a significant increase in live 
hemSCs number and only at 100 µM quinidine did it significantly decrease 
hemSCs growth compared with control (Figure 16).  This profile is identical to the 
one seen with propranolol at 25 and 100 µM after 72 hours (Figure 3B).  
Surprisingly, HDMECs were unaffected at all concentrations of quinidine used 
when compared with control (Figure 16).  Our data suggest that the cellular 
components of hemSCs and HDMECs are quite different, and it would be 
important to investigate whether the decrease in hemSCs upon 100 µM quinidine 
is due to apoptosis and/or cell cycle arrest.  Furthermore, our findings highlight 
the importance of understanding the cellular receptor components to target 
hemSCs.  Our study demonstrates that although hemSCs are responsive to 
propranolol by inhibiting cellular growth and inducing anti-apoptotic genes, the 
mechanism by which propranolol mediates its effects in hemSCs are through β-
ADR-independent effects. 
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4.1.1 Concluding remarks 
Propranolol has shown promising effects in IH resolution and many studies have 
sought to understand the mechanism of propranolol’s effective treatment.  
Although the mechanism of action is not fully understood, our study represents 
an important step towards understanding propranolol’s action.  Our findings 
provide novel insight into the possibility that propranolol may affect hemangioma-
initiating cells (hemSCs) through a β-adrenergic receptor-independent pathway, 
potentially involving 5-HTRs and membrane stabilization.  Identification of 
cytoplasmic regulatory proteins in hemSCs that interact with β-ADR and 5-HTRs 
may represent an attractive future research area for the development of cell-type 
specific therapies. 
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4.2 Future Direction 
Although propranolol is efficacious, there is quite a bit of knowledge gap.  There 
are possibilities that need to be explored: 1) involvement of receptor dimerization 
and α-ADR signaling, 2) involvement of 5-HT signaling, and 3) role of membrane 
stabilizing effects.   
Although data is limited, propranolol does stereoselectively bind and inhibit α-
ADR in the heart [111].  Immunoprecipitation studies also show that β1-ADR and 
α2-ADR heterodimerize when co-expressed [112].  This interaction changes the 
pharmacological properties of β1-ADR as shown by ligand binding assays.  β1- 
and β2- ADR have also been shown to heterodimerize [113, 114].  These 
findings suggest that the profile of ADR receptors may have functional cellular 
consequence and represents an area of significant future research interest.  In 
addition, our data suggest that β1-ADR is the key receptor that mediates 
apoptosis in HDMECs, and since hemSCs β1-ADR level is hardly detectable, 
apoptosis is not evident in this cell type.  Therefore, it would be interesting to 
investigate whether overexpression of β1-ADR in hemSCs would induce 
apoptosis upon propranolol exposure.   
Moreover, a number of pressing questions remain.  For example, is propranolol 
selective to IH vessels? Based on recent findings in endothelial cells (normal vs 
IH-derived) and our own findings in hemSCs, this seems unlikely.  Alternatively, 
the effectiveness of propranolol in IHs may be a function of increased levels that 
are sustained in the capillary mass of IHs.   
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Lastly, are there better alternatives to propranolol? Further studies need to be 
conducted to determine whether activation of 5-HTRs can induce apoptosis 
and/or reduce anti-apoptotic genes.  This would allow for alternative treatments 
to target 5-HTRs rather than β-ADRs as it is highly expressed in hemSCs.  Also, 
based on our data, nadolol has similar growth effect in hemangioma-derived 
stem cells to propranolol.  Therefore, further studies are needed to determine 
whether similar anti-apoptotic gene profile is induced, and whether it can induce 
apoptosis in hemSCs to prevent recurrence of hemangiomas.  Moreover, it would 
be interesting to observe the receptor profile after nadolol exposure and compare 
to the changes of propranolol’s receptor profile. 
These studies are underway in our laboratory and the findings may enhance our 
understanding of the mechanism of therapeutic action of propranolol and may 
provide more effective treatment options.  
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Appendix A: Representation of β1-ADR melting curve analysis in hemSCs 
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